ACP
CLRB icon

Acuta Capital Partners’s Cellectar Biosciences CLRB Stock Holding History

Acuta Capital Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,350
Closed -$176K – 43
2024
Q2 		$176K Sell
2,350
-2,433
-51% -$233K 0.15% 31
2024
Q1 		$571K Sell
4,783
-11,134
-70% -$1.21M 0.37% 32
2023
Q4 		$1.32M Buy
15,917
+11,874
+294% +$885K 0.74% 31
2023
Q3 		$320K Buy
+4,043
New +$238K 0.21% 40

Other funds holding CLRB

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acuta Capital Partners's CLRB Position: Q3 2024 in Review

Acuta Capital Partners sold out of Cellectar Biosciences (CLRB) in Q3 2024, closing a stake of 2,350 shares — an estimated $176K sold.

Acuta Capital Partners first reported a position in CLRB in Q3 2023 and held it in 4 quarters. The position peaked at $1.32M in Q4 2023. 35 funds tracked by Wall St. Rank hold CLRB as of Q3 2024.

  • Acuta Capital Partners reported no remaining Cellectar Biosciences position as of Q3 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 2,350 Cellectar Biosciences shares in Q3 2024, an estimated $176K.
  • Acuta Capital Partners first reported a position in Cellectar Biosciences in Q3 2023 and held it in 4 quarters.
  • Acuta Capital Partners's Cellectar Biosciences position peaked at $1.32M in Q4 2023.
  • 35 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.